A pilot study on the effect of lactoferrin on Alzheimer’s disease pathological sequelae: Impact of the p-Akt/PTEN pathway
| Autor: | Rania M. Salama, Waleed A. Mohamed, Mona F. Schaalan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty PTEN Inflammation Pilot Projects RM1-950 medicine.disease_cause 03 medical and health sciences 0302 clinical medicine Alzheimer Disease Internal medicine medicine Tensin Humans Cognitive decline Neurodegeneration Protein kinase B PI3K/AKT/mTOR pathway Aged Pharmacology PI3K/Akt biology business.industry PTEN Phosphohydrolase General Medicine medicine.disease Lactoferrin 030104 developmental biology Endocrinology Treatment Outcome 030220 oncology & carcinogenesis biology.protein Leukocytes Mononuclear Female Therapeutics. Pharmacology medicine.symptom business Proto-Oncogene Proteins c-akt Alzheimer’s disease Oxidative stress Signal Transduction |
| Zdroj: | Biomedicine & Pharmacotherapy, Vol 111, Iss, Pp 714-723 (2019) |
| ISSN: | 0753-3322 |
| Popis: | Alzheimer's disease (AD) is one of the most common neurodegenerative diseases in which the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (PKB or Akt) pathway is deregulated in response to phosphatase and tensin homolog (PTEN) overexpression. Lactoferrin (LF), a multifunctional iron-binding glycoprotein, is involved in AD pathology; however, direct evidence of its impact upon AD remains unclear. To elucidate LF's role in AD, the possible protective mechanism post-LF administration for 3 months was investigated in AD patients by observing changes in the p-Akt/PTEN pathway. AD patients showed decreased serum acetylcholine (ACh), serotonin (5-HT), antioxidant and anti-inflammatory markers, and decreased expression of Akt in peripheral blood lymphocytes (PBL), as well as PI3K, and p-Akt levels in PBL lysate; all these parameters were significantly improved after daily LF administration for 3 months. Similarly, elevated serum amyloid β (Aβ) 42, cholesterol, oxidative stress markers, IL-6, heat shock protein (HSP) 90, caspase-3, and p-tau, as well as increased expression of tau, MAPK1 and PTEN in AD patients, were significantly reduced upon LF intake. Improvement in the aforementioned AD surrogate markers post-LF treatment was reflected in enhanced cognitive function assessed by the Mini-Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale-Cognitive Subscale 11-item (ADAS-COG 11) questionnaires as clinical endpoints. These results provide a basis for a possible protective mechanism of LF in AD through its ability to alleviate the AD pathological cascade and cognitive decline via modulation of the p-Akt/PTEN pathway, which affects the key players of inflammation and oxidative stress that are involved in AD pathology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect